David A Lowe

Title: David A. Lowe: Innovator in Neurodegenerative Disease Treatment

Introduction

David A. Lowe is a notable inventor based in Park Ridge, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurodegenerative diseases. His innovative work focuses on developing compounds that can potentially improve the lives of those affected by these conditions.

Latest Patents

David A. Lowe holds 1 patent for his invention titled "Compounds for treatment of neurodegenerative diseases." This patent relates to a class of small molecule hydroxamic acid compounds capable of inhibiting histone deacetylases (HDACs). The invention also encompasses methods for preparing these hydroxamic acid HDAC inhibitor compounds, specifically N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives. Furthermore, it includes their incorporation into pharmaceutical compositions and methods of administration. The patent highlights the potential for creating a hydroxamic acid HDAC inhibitor compound library that can be utilized in various screening methods.

Career Highlights

David A. Lowe is associated with Envivo Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work at the company emphasizes the importance of innovative solutions in the pharmaceutical industry, particularly for neurodegenerative diseases.

Collaborations

Throughout his career, David has collaborated with notable colleagues, including William Charles Ripka and Christopher J. Cummings. These collaborations have likely contributed to the success and development of his innovative ideas and patents.

Conclusion

David A. Lowe is a prominent figure in the field of neurodegenerative disease treatment, with a focus on innovative compounds that hold promise for future pharmaceutical applications. His contributions through patents and collaborations underscore the importance of research in improving health outcomes.